Introduction
============

Tuberculosis (TB) is a disease caused by *Mycobacterium tuberculosis* complex (MTBC). It is one of the leading causes of deaths from single infectious diseases and ninth from any cause of deaths worldwide.[@b1-idr-11-1581] The therapeutic effectiveness of agents plays a very crucial role in the control of TB. The discovery of effective TB treatment, streptomycin (STR) in 1940s[@b2-idr-11-1581],[@b3-idr-11-1581] to rifampicin (RIF) in 1960s,[@b4-idr-11-1581],[@b5-idr-11-1581] made experts in the area to feel that it is time to end TB. But the emergence of resistant strains of *M*. *tuberculosis* has created a major threat to the control of TB.[@b6-idr-11-1581] Multidrug resistant TB (MDR-TB) has reached to epidemic proportions in some countries.[@b7-idr-11-1581]

Globally, the proportions of MDR/RIF-resistant TB were estimated to be 4.1% in new TB cases and 19.0% in previously treated TB cases in 2016.[@b1-idr-11-1581] About 6.2% MDR-TB cases were extensively drug resistant (XDR)-TB.[@b1-idr-11-1581] Ethiopia stands 14th among the 30 high MDR-TB burden countries.[@b1-idr-11-1581] Early detection of drug resistance is essential for appropriate treatment and prevention of further spread of resistant strains.[@b8-idr-11-1581] However, drug sensitivity test (DST) is not accessible to all TB patients in Ethiopia due to inadequate laboratory capacity, inadequate transport network and resource limitation.[@b9-idr-11-1581],[@b10-idr-11-1581] Phenotypic DST is considered as the gold standard but it is done in limited laboratories in Ethiopia. Accordingly, 10.0% of pulmonary MDR-TB cases were detected and the patients received treatment.[@b11-idr-11-1581] The remaining 90% were most likely undiagnosed and being a source of infection or started treatment based on patient history. Therefore, strengthening the DST in the country is important.

Liquid culture: BACTEC MGIT 960 system[@b12-idr-11-1581] and molecular techniques including GenoTypeMTBDR*plus*[@b13-idr-11-1581] and Gene Xpert MTB/RIF,[@b14-idr-11-1581] can detect drug resistance easier and faster. The presence of a mutation in *rpoB* gene[@b15-idr-11-1581] leads to resistance for RIF and mutations in *inhA* gene[@b16-idr-11-1581] and/or in *katG* gene[@b17-idr-11-1581] lead to resistance for isoniazid (INH). BACTEC MGIT System, GeneXpert MTB/RIF and GenoTypeMTB-DR*plus* assays are recently introduced in Ethiopia and are used for the detection of MDR-TB in selected health facilities and research centers. Although molecular assays can rapidly detect MTBC and mutation associated with drug resistance in a day(s), it should be complemented by phenotypic DST.[@b18-idr-11-1581]

Surveillance of drug-resistant TB in a population of specific localities such as South Omo Zone, which is a pastoral area and located at the periphery in the southern Ethiopia, has a crucial role to optimize drug treatment and to tackle the dissemination of resistant MTBC strains in the area. Therefore, this study was carried out with the objective of evaluating drug sensitivity of MTBC isolated from South Omo, southern Ethiopia using MGIT 960 system and GenoType MTBDR*plus* assay.

Materials and methods
=====================

Study setting
-------------

South Omo Zone is located in southern Ethiopia and borders Kenya and South Sudan[@b19-idr-11-1581],[@b20-idr-11-1581] and consists of eight districts and one city administration (Jinka). Zone is situated at 4.43°--6.46° latitude and 35.79°--36.06° longitude. According to the 2007 census, the total population of Zone was 577,673 (7.5% urban and 92.5% rural) of whom 50% were men.[@b21-idr-11-1581] Jinka General Hospital (JGH) is the only Hospital in Zone and has been functional since April 2001.[@b22-idr-11-1581] JGH provides health services for about 1,000,000 people from its catchment area in and outside the Zone. JGH was the main sample collec tion site. Human subject recruitment and sample collection were also conducted in 12 other health centers from different districts using community-based screening.

Ethical clearance
-----------------

Ethical clearance was obtained from Aklilu Lemma Institute of Pathobiology, Addis Ababa University (ALIPB-AAU) Institutional Review Board (ref. no. ALIPB/IRB/22-B/2012/13) and the National Research Ethics Committee (ref no. 3.10/785/07). Permission to conduct the study was also obtained from South Omo Zone Health Department. Written informed consent was obtained from study participants.

MTBC Isolates
-------------

The TB molecular epidemiological study was undertaken in South Omo Zone from September 2014 to May 2016. A total of 1200 sputum and fine needle aspirate samples were collected from TB cases and TB-suspected individuals in health centers through screening of the community. All 1200 samples were cultured on Lowenstein Jensen medium, yielding 201 acid fast bacilli (AFB) isolates of which 161 were part of the MTBC. Twenty-eight isolates were non-tuberculosis mycobacteria and 12 isolates were not members of the genus *Mycobacterium*. The AFB isolates were differentiated into three groups using region difference-based PCR[@b9-idr-11-1581],[@b23-idr-11-1581] and genus typing multiplex PCR.[@b24-idr-11-1581] In addition, the species were identified based on the spoligotyping pattern according to Kamerbeek et al.[@b25-idr-11-1581] MTBC isolates were stored in freezing medium and their DNA was extracted in dH~2~O. For DST analysis, the frozen suspension of the MTBC isolates were thawed and tested for DST using the BACTEC MGIT 960 system. Additionally, the frozen DNA of MTBC isolates were tested for DST using the GenoType MTBDR*plus* assay.

Phenotypic DST for first-line drugs using the BACTEC MGIT 960 system
--------------------------------------------------------------------

Phenotypic DST of MTBC isolates to the first-line drugs was done using BD BACTEC™ MGIT™ 960 system in the Mycobacteriology Research Center at Jimma University (MRC-JU). The BACTEC MGIT™ (Becton Dickinson, Franklin Lakes, NJ, USA). Procedure was followed as described in its manual.[@b26-idr-11-1581] The frozen MTBC isolates were thawed and then 100 µL of aliquots was added into 2 mL of phosphate-buffered saline and processed for decontamination using equal volume of 2.9% sodium citrate and 4% sodium hydroxide solution. Thereafter, the decontaminated suspension of isolates was cultured using the MGIT 960 system. Lyophilized preparations of the antibiotic drugs of MGIT 960 SIRE kit and pyrazinamide (PZA) kit were reconstituted in sterile dH~2~O. Final concentrations of STR 1.0 µg/mL, INH 0.1 µg/mL, RIF 1.0 µg/mL, ethambutol (EMB) 5.0 µg/mL and PZA 100.0 µg/mL were used. A growth control (GC) tube without drug was included for each isolate. The relative growth ratio between the drug-containing tube and GC tube was determined by the BD BACTEC™ MGIT™ 960 system's software algorithm when 400 growth units for the GC tube were reached. DST results were reported qualitatively. Quality control was maintained by testing the batch of MGIT medium, SIRE Kit and PZA kit using the strain *M*. *tuberculosis* H37Rv.

Detection of RIF and INH resistance using GenoType^®^ MTBDRplus assay
---------------------------------------------------------------------

The identification of genotypic drug resistance to RIF (based on mutations the *rpoB* gene) and INH (based on mutations in *katG* and *inhA* genes) was carried out using the manufacturer's instruction[@b27-idr-11-1581] in the TB Laboratory at ALIPB-AAU. Accordingly, 50 µL of PCR mixture consisting of 10 µL AM-A GT MTBDR*plus* ver 2.0, 35 µL AM-B GT MTBDR*plus* ver 2.0 and 5µL DNA template from an isolate was used to perform this assay. *M*. *tuberculosis* H~37~Rv DNA template was used as a positive control. Water (Qiagen NV, Venlo, the Netherlands, product) served as a negative control. A thermal cycler (VWR, Leicestershire, UK) was programmed as follows: 15 min for enzyme activation at 95°C followed by 10 cycles of 30 sec denaturation at 95°C, 2 min annealing at 58°C, 20 cycles of 25 sec denaturation at 95°C, 40 sec annealing at 53°C, 40 sec elongation at 70°C, and finally elongation at 70°C for 8 min. Biotin-labeled amplicons were hybridized to DNA probes attached to a DNA strip^®^. Hybridization was done using the TwinCubator (Hain Lifescience, Nehren, Germany). Results were interpreted based on the presence and absence of wild-type (WT) and mutation (MUT) probes.

Data analysis
-------------

Data analysis was performed using IBM SPSS Statistics 20. Descriptive summaries are presented in [Tables 1](#t1-idr-11-1581){ref-type="table"} and [2](#t2-idr-11-1581){ref-type="table"}. Performance of the MTBDR*plus* assay in the diagnosis of RIF and INH resistance was evaluated taking results from the MGIT 960 test as gold standard. The association between drug resistance and other independent variables was evaluated using logistic regression models. *P*-values of less than 0.05 were considered as statistically significant.

Results
=======

Demographic and clinical characteristics of study participants
--------------------------------------------------------------

Demographic and clinical characteristics of the 161 study participants are summarized in [Table 1](#t1-idr-11-1581){ref-type="table"}. About 40% of the study participants were females. The age range of the study participants varied from 15 to 80 years with a mean and SD of 33.2 and 13.1 years, respectively. The majority (82%) of the participants were in the age range between 15 and 44 years. Age (*P*=0.017) and type of TB (*P*=0.005) were significantly associated with residential place.

Phenotypic drug sensitivity patterns as detected by MGIT 960 system
-------------------------------------------------------------------

Phenotypic DST could be done on 78.3% (126/161) of the MTBC isolates ([Figure 1](#f1-idr-11-1581){ref-type="fig"}) and the result is summarized in [Table 2](#t2-idr-11-1581){ref-type="table"}. About 91% of the isolates from the new TB case were pan-susceptible to anti-TB drugs, while four of the seven isolates from the re-treatment case isolates were pan-susceptible to anti-TB drugs. Mono-drug resistance was observed in 9.2% (11/119) of the isolates of the new TB cases. The highest incidence of mono-drug resistance was observed to PZA (5.9%) followed by STR (2.5%). Polydrug resistance and MDR were observed in two and one of the seven re-treatment cases, respectively. The results are summarized in [Table 2](#t2-idr-11-1581){ref-type="table"}.

Phenotypic drug resistance and its association with demographic characteristics
-------------------------------------------------------------------------------

A summary result of the logistic regression indicating the association of phenotypic drug resistance and selected demographic characteristics is presented in [Table 3](#t3-idr-11-1581){ref-type="table"}. The re-treatment TB cases were significantly associated with increased odds of having drug-resistant isolates compared to the new TB cases (AOR=11.60, 95% CI: 1.70--78.92).

Genotypic drug resistance data
------------------------------

Genotypic DST results of selected 13 isolates out of 158 susceptible isolates and all the three isolates, which showed resistance, are depicted in [Figure 2](#f2-idr-11-1581){ref-type="fig"}. As observed in [Figure 2](#f2-idr-11-1581){ref-type="fig"}, RIF mono-drug resistance was 1.3% (2/153) in the new TB cases. One of these two isolates had known CAC→GAC mutation resulting in the amino acid substitution at H526D, while the other isolate had a missing *rpoB*-WT8 without a known mutation. One MDR-TB case was identified for eight TB re-treatment TB cases. The MDR isolate had a GAC→GTC mutation in *rpoB* (amino acid substitution D516V) and an AGC→ACA mutation in *katG* (amino acid substitution S315T2).

Genotype MTBDRplus assay performance compared to MGIT 960 system
----------------------------------------------------------------

The diagnostic performance of the MTBDR*plus* assay was evaluated by the MGIT 960 system on 126 MTBC isolates. As summarized in [Table 4](#t4-idr-11-1581){ref-type="table"}, the sensitivities of the MTBDR*plus* assay for detection of resistance to INH, RIF and MDR were 33.3%, 100% and 100%, respectively. Its specificities for the detection of resistance to INH, RIF and MDR were 100%, 99.2% and 100%, respectively. One isolate showed RIF resistance to genotypic DST but not to phenotypic DST. On the contrary, two isolates showed INH resistance to phenotypic DST but not to genotypic DST.

Discussion
==========

In the present study, the DST was performed on 161 MTBC isolates, which were isolated from clinical cases in South Omo Zone, southern Ethiopia. The findings of this study are expected to be useful for the TB Control Program of Zone and would serve as baseline data for future studies.

Majority of the isolates were recovered from the economically productive age group, and this observation is similar with observation made by the previous studies.[@b28-idr-11-1581]--[@b31-idr-11-1581] The reason could be due to the mobility of this age group for economy and social reasons. Similarly, relatively large number of isolates were recovered from males than females which is in agreement with the WHO report.[@b1-idr-11-1581] This could be attributed to the difference between the two sex groups in biological, societal role and access to health facilities.[@b32-idr-11-1581]

In this study, 90.8% of the isolates of the new TB cases were phenotypically pan-susceptible and mono-drug resistance was observed relatively in lower percentage when compared with the percentage reported by the national survey.[@b33-idr-11-1581] The highest mono-drug resistance was observed against PZA and similar observations were made in Quebec[@b34-idr-11-1581] and People's Republic of China.[@b35-idr-11-1581] PZA is part of the first- and the second-line anti-TB drugs[@b10-idr-11-1581] and helps to shorten the duration of TB treatment.[@b36-idr-11-1581] PZA resistance is associated with less probable of treatment success.[@b37-idr-11-1581] Hence, the existence of more PZA-resistant isolates in the study area could have an impact on TB Control Program of the area. Two of the PZA-resistant isolates in this study were *M*. *bovis*, which are naturally resistant to PZA.[@b38-idr-11-1581]

In this study, STR mono-drug-resistance in the new TB cases was the second higher proportion next to PZA. This finding is similar with those reported by the previous studies in Ethiopia[@b29-idr-11-1581],[@b33-idr-11-1581],[@b39-idr-11-1581]--[@b41-idr-11-1581] and could be due to the widespread use of STR for treatment of the other bacterial infections.[@b42-idr-11-1581],[@b43-idr-11-1581] The least percentage to resistance was observed against EMB and this observation is in agreement with the results reported by earlier studies.[@b29-idr-11-1581],[@b33-idr-11-1581],[@b39-idr-11-1581]--[@b41-idr-11-1581] No resistance was observed either against INH or against RIF in isolates of the new TB cases. But mono-resistance was observed against INH in the re-treatment cases and was associated with poor treatment outcomes.[@b44-idr-11-1581] Hence, strengthening case management could help to avert the effect of INH resistance. The proportion of MDR-TB in the re-treatment TB cases was similar to that of one study reported earlier,[@b41-idr-11-1581] while it was less than those reported by the other studies.[@b29-idr-11-1581]--[@b31-idr-11-1581],[@b40-idr-11-1581] However, it was difficult to make a reliable comparison because of the small sample size of the re-treatment cases in this study.

One of the isolates recovered from the re-treatment TB cases was resistant to both RIF and INH (MDR)and the majority (95%) of RIF resistance occurred within RIF resistance determining region with 81 bp length when there is a mutation in the *rpoB* gene.[@b15-idr-11-1581] Mutations in the *katG*, *inhA* and *ahp*C genes lead to INH resistance, which does not occur in a specific region like that of RIF resistance.[@b45-idr-11-1581] Mostly *katG* gene mutation is associated with high-level resistance.[@b46-idr-11-1581] The MDR isolate missed *rpoB* WT3 and *rpoB* WT4 genes and had a mutation at *rpoB*MUT1 with an amino acid change of D516V (GAC→GTC),which is a synonym of D435V (GAC→GTC).[@b47-idr-11-1581] This isolate, in addition, missed WT *katG* gene and developed *katG* MUT2 with an amino acid change of S315T2 (AGC→ACA). Similarly, such *rpoB* gene mutation types were observed at low frequency in studies conducted in Ethiopia[@b48-idr-11-1581] and Pakistan,[@b49-idr-11-1581] and at high frequency in a study conducted in East Hungary.[@b50-idr-11-1581] The amino acid change of S315T2 (AGC→ACA) in this isolate was not previously reported from Ethiopia but the most common reported amino acid change in Ethiopia has been S315T1, which is in the range of 83%--100%.[@b28-idr-11-1581],[@b48-idr-11-1581],[@b51-idr-11-1581]--[@b53-idr-11-1581]

One of RIF mono-resistant isolates missed *rpoB* WT7 gene and developed mutation at *rpoB* MUT2B with an amino acid change of H526D, which is a synonym of H445D.[@b47-idr-11-1581] Such type of mutation with an amino acid change of H526D was previously reported in Ethiopia in the proportion of 0%--22%.[@b28-idr-11-1581],[@b48-idr-11-1581],[@b51-idr-11-1581],[@b53-idr-11-1581] The other RIF mono-resistant isolate missed *rpoB* WT8 and had no known mutation, which may not indicate real resistance but rather it could be due to a silent mutation in *rpoB* gene.[@b54-idr-11-1581] Similarly, such resistance was reported in previous studies of Ethiopia with various proportions including 11.8%[@b53-idr-11-1581] and 44.4%.[@b51-idr-11-1581] But most RIF-resistant isolates missing *rpoB* WT8 are accompanied by an S531L amino acid change.[@b28-idr-11-1581],[@b48-idr-11-1581],[@b53-idr-11-1581],[@b55-idr-11-1581] RIF mono-resistant isolates were identified from the new TB cases, which could be acquired from TB patients who had RIF-resistant TB or the patients could previously be treated with RIF for other bacterial infection.[@b42-idr-11-1581],[@b43-idr-11-1581] Molecular detection of RIF resistance is used as a surrogate marker for MDR-TB.[@b11-idr-11-1581],[@b13-idr-11-1581],[@b28-idr-11-1581] Hence, the identification of RIF-resistant and MDR isolates in the present study indicated the existence of MDR-TB in the study area, which highlights the need for strengthening of the TB control program in the study area.

The sensitivity of GenoType MTBDR*plus* assay for detection of INH resistance in the present study was lower than those reported by previous studies in Ethiopia,[@b48-idr-11-1581],[@b51-idr-11-1581] Uganda[@b55-idr-11-1581] and Pakistan.[@b49-idr-11-1581] The MTBDR*plus* assay was not able to detect the INH resistance in the two isolates, which were detected by MGIT 960 system. This could be due to mutations in the *inhA* promoter and the ahpC-oxyR intergenic regions, which have not been included in the strips[@b56-idr-11-1581] or it could also be due to unidentified mutation. The high specificity of the MTB-DR*plus* assay in detecting INH resistance, RIF resistance and MDR MTBC isolates agrees with the specificity of previous studies.[@b48-idr-11-1581],[@b51-idr-11-1581],[@b55-idr-11-1581] RIF resistance in one isolate was detected by the MTBDR*plus* assay but not by MGIT 960 system. Being susceptible by phenotypic method but resistant by genotypic method may be associated with false RIF resistance due to a silent mutation which make the probe fails to hybridize on a strip and interpreted as RIF resistant.[@b57-idr-11-1581] The three isolates that created discordance between the assays used need further analysis by DNA sequencing to fully understand reasons for the observed discordance.

Conclusion
==========

The magnitude of drug resistance was relatively low in new TB cases of South Omo as compared to those reported from the other regions of the country. This is encouraging, and hence, the TB Control Program in Zone should strengthen its program and make continuous surveillance so that early detection enables the concerned bodies to take appropriate actions to inhibit the emergence of drug resistance in South Omo.
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![Genotypic DST results of selected susceptible isolates and all resistant isolates.\
**Notes:** Three isolates (SO-0025, SO-0130 and SO-0227) were resistant to RIF and/or INH and the rest 13 isolates were susceptible to both RIF and INH as representative for the 158 susceptible isolates to RIF and INH. In this illustration, isolate SO-0130 was from the re-treatment TB case and the remaining 15 isolates were from the new TB cases.\
**Abbreviations:** DST, drug sensitivity test; RIF, rifampicin; INH, isoniazid; TB, tuberculosis; CC, conjugate control; AC, amplification control; WT, wild-type probe; MUT, mutation probe; TUB, *M. tuberculosis* complex.](idr-11-1581Fig2){#f2-idr-11-1581}

###### 

Demographic and clinical characteristics of study participants

  Characteristics         Total N (%)   Number (%) of study participants   *P*-value                
  ----------------------- ------------- ---------------------------------- ----------- ------------ -------
  Sex                                                                                               
   Female                 64 (39.8)     30 (42.9)                          26 (36.6)   8 (40.0)     0.751
   Male                   97 (60.2)     40 (57.1)                          45 (63.4)   12 (60.0)    
  Age in years                                                                                      
   15--29                 72 (44.7)     32 (45.7)                          34 (47.9)   6 (30.0)     0.017
   30--44                 60 (37.3)     28 (40.0)                          19 (26.8)   13 (65.0)    
   45+                    29 (18.0)     10 (14.3)                          18 (25.4)   1 (5.0)      
  Type of TB                                                                                        
   PTB+                   110 (68.3)    48 (68.6)                          49 (69.0)   13 (65.0)    0.005
   PTB−                   25 (15.5)     5 (7.1)                            13 (18.3)   7 (35.0)     
   EPTB                   26 (16.1)     17 (24.3)                          9 (12.7)    0 (0.0)      
  Treatment history                                                                                 
   New TB case            153 (95.0)    68 (97.1)                          65 (91.5)   20 (100.0)   0.171
   TB re-treatment case   8 (5.0)       2 (2.9)                            6 (8.5)     0 (0.0)      
   Total                  161 (100)     70 (43.5)                          71 (44.1)   20 (12.4)    

**Abbreviations:** TB, tuberculosis; PTB+, smear-positive pulmonary TB; PTB--, smear-negative pulmonary; TB; EPTB, extra-pulmonary TB.

###### 

Phenotypic DST results for 126 MTBC isolates

  TB cases                     No. of Isolates   First-line anti-TB drugs   PZA       DR type   \%                            
  ---------------------------- ----------------- -------------------------- --------- --------- --------- --------- --------- ---------
  **New (N=119)**              **108 (90.8)**    S                          S         S         S         S         Pan-S     90.8
  **3 (2.5)**                  R                 S                          S         S         S         Mono      9.2       
  **1 (0.8)**                  S                 S                          S         R         S                             
  **7 (5.9)**                  S                 S                          S         S         R                             
                                                                                                                              
  **Re-treatment (N=7)**       **4 (57.1)**      S                          S         S         S         S         Pan-S     57.1
  **2 (28.6)**                 S                 R                          S         S         R         Poly      28.6      
  **1 (14.3)**                 R                 R                          R         R         R         MDR       14.3      
                                                                                                                              
  **Any resistance (N=126)**   **14 (11.1)**     **3.2**                    **2.4**   **0.8**   **1.6**   **7.9**   **MDR**   **0.8**

**Abbreviations:** DST, drug sensitivity test; MTBC, *Mycobacterium tuberculosis* complex; TB, tuberculosis; STR, streptomycin; INH, isoniazid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide; DR type, drug-resistance type; S, susceptible; Pan-S, pan-susceptible; R, resistant; MDR, multidrug resistance.

###### 

Demographic factors associated with phenotypic drug resistance of MTBC isolates

  Characteristics                                               Total N (%)   DR N (%)    Crude OR (95% CI)    Adjusted OR (95% CI)   *P*-value
  ------------------------------------------------------------- ------------- ----------- -------------------- ---------------------- -----------
  Sex                                                                                                                                 
   Female                                                       48 (38.1)     7 (14.6)    1.00                 1.00                   
   Male                                                         78 (61.9)     7 (9.0)     0.58 (0.19--1.76)    0.55 (0.15--1.98)      0.357
  Age in years                                                                                                                        
   15--29                                                       56 (44.4)     6 (10.7)    1.00                 1.00                   
   30--44                                                       48 (38.1)     4 (8.3)     0.76 (0.20--2.86)    0.68 (0.16--2.86)      0.601
   \>=45                                                        22 (17.5)     4 (18.2)    1.85 (0.47--7.33)    0.11 (3.95)            0.643
  TB type                                                                                                                             
   PTB+                                                         84 (66.7)     10 (11.9)   1.00                 1.00                   
   PTB−                                                         19 (15.1)     2 (10.5)    0.87 (0.18--4.34)    0.42 (0.04--4.77)      0.483
   EPTB                                                         23 (18.3)     2 (8.7)     0.71 (0.14--3.47)    0.50 (0.09--2.77)      0.426
  Treatment history                                                                                                                   
   New TB cases                                                 119 (94.4)    11 (9.2)    1.00                 1.00                   
   Re-treatment TB cases                                        7 (5.6)       3 (42.9)    7.36 (1.46--37.22)   11.60 (1.70--78.92)    0.012
  Residential area[a](#tfn3-idr-11-1581){ref-type="table-fn"}                                                                         
   Non-pastoral                                                 54 (42.9)     8 (14.8)    1.00                 1.00                   
   Pastoral                                                     56 (44.4)     5 (8.9)     0.56 (0.17--1.85)    0.46 (0.12--1.70)      0.241

**Note:**

Participants with unknown residences were excluded from logistic regression analysis.

**Abbreviations:** MTBC, *Mycobacterium tuberculosis* complex; DR, drug resistance; TB, tuberculosis; PTB+, smear-positive pulmonary TB; PTB--, smear-negative pulmonary.

###### 

GenoType MTBDR*plus* assay performance evaluation compared to MGIT 960 system

                                             MGIT 960 system   Total   Diagnostic performance of GenoType MTBDR*plus* assay   Level of agreement                           
  ---------------------------- --------- --- ----------------- ------- ------------------------------------------------------ -------------------- ----- ----- ----------- -----------
  GenoType MTBDR*plus* assay   **INH**   R   1                 0       1                                                      33.3                 100   100   98.4        **0.494**
                               S         2   123               125                                                                                                         
  **RIF**                      R         1   1                 2       100                                                    99.2                 50    100   **0.663**   
                               S         0   124               124                                                                                                         
  **MDR**                      R         1   0                 1       100                                                    100                  100   100   **1.00**    
                               S         0   125               125                                                                                                         

**Abbreviations:** R, resistant; S, susceptible; PPV, positive predictive value; NPV, negative predictive value; INH, isoniazid; RIF, rifampicin; MDR, multidrug resistance.
